Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.56 |
| ▸ | ACHE | P22303 | 3/20 | 0.56 |
| ▸ | BACE1 | P56817 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 9/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | TEAD1 | P28347 | 3/20 | 0.50 |
| ▸ | LSS | P48449 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856132 | 0.91 | ALDH1A1 (0.64) | BCHEACHEBACE1ALDH1A1TSHR | |
| Trifluoroacetic Acid SCHEMBL1921476 | 0.88 | SIGMAR1 (0.55) | ACHECHRM2 | |
| Trifluoroacetic Acid SCHEMBL1920766 | 0.84 | SIGMAR1 (0.53) | — | |
| Trifluoroacetic Acid SCHEMBL1920595 | 0.84 | ARG1 (0.52) | ALDH1A1TEAD1 | |
| SCHEMBL5542857 | 0.80 | ALDH1A1 (0.64) | BCHEACHEBACE1ALDH1A1TSHR | |
| Trifluoroacetic Acid SCHEMBL1921350 | 0.79 | MCHR1 (0.58) | ACHE | |
| SCHEMBL3599853 | 0.78 | CHRM2 (0.60) | BCHEACHEBACE1CHRM4CHRM2 | |
| SCHEMBL3599854 | 0.78 | CCR5 (0.58) | BCHEACHEBACE1ALDH1A1TSHR | |
| SCHEMBL13478353 | 0.78 | ALDH1A1 (0.61) | BCHEACHEBACE1ALDH1A1TSHR | |
| SCHEMBL4704073 | 0.78 | SPHK1 (0.55) | BCHEACHEBACE1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622914-B1 | NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | TROVIS PHARMACEUTICALS LLC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7030240-B2 | 5-HT receptor antagonist; [1-(2-Fluoro-benzyl)-piperidin-4-yl]-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine; treating vascular disorders, angina, migraine, pulmonary hypertension and systemic hypertension | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | TROVIS PHARMACEUTICALS, LLC | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | HTR5A, HTR2C, HTR1A | BCHE 3826/4885ACHE 1151/4885BACE1 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.